Evgen Pharma Share Discussion Threads

[kingalf] 17/10/2023 17:08

Surely that would apply to all companies then, they all have some form of inside information. Just a load of bull xxxx, whatever they were concerned about should have been announced by now, and as it hasn't it's clearly not on the radar anymore

[clocktower] 17/10/2023 16:06

Kingalf - your forgetting, they have been advised in 2022 that they cannot buy shares because of their inside knowledge.🤣🤣🤣

[clocktower] 17/10/2023 15:59

Even with more buys than sells the MM walk it down.

ACRL moving up nicely if anyone fancies a look. DYOR

[kingalf] 17/10/2023 15:47

If I were running a business and my share holders were suffering I would by now have a financial vested interest just so I could be seen to be sharing the pain. I wouldn't expect to give out a running daily commentary, but some news with progress or lack of it should be a minimum. Clearly the current bods have no experience of running a business, rabbits in headlights comes to mind.

[paulhudd] 13/10/2023 10:07

Don't worry my target is 1.4 then I may consider getting back in

[hatfullofsky] 13/10/2023 09:42

Chill Clock, no point watching every trade, wait for the news

[clocktower] 13/10/2023 09:11

So the seller/sellers remain in control and it seems to me they have just been waiting to see if PI's will buy because they are bottom fishing, so they can continue to unload, as it maybe what the company expected, hence no director buying decent amounts.

[clocktower] 12/10/2023 15:35

I spoke to soon now on offer 1.828p

[clocktower] 12/10/2023 15:16

This time they have not dropped the offer a fraction after a purchase of 55k odd, so are they reaching the bottom of the barrel from the previous weeks sells?

Still 1.83p to buy, and this week we have seen buys far out weight sells - ti date anyway!

[wololol] 12/10/2023 14:26

Yes 900 thousand euros to start with

[markth126] 12/10/2023 13:16

Was the value of the grant received in June for the trials ever disclosed?

[clocktower] 12/10/2023 11:47

Even cheaper at the last trade buy, and I just got a quote and the offer is 1.83p going down with every buy - something is cooking, as this has gone on all week Wololol.

[wololol] 12/10/2023 08:59

Whatever happens , I know the company is worth as least 3 times the price from where is is now. Trading close to cash. 10s of millions of R and D and IP. Happy to wait and at least double money over the next few weeks/months

[clocktower] 12/10/2023 07:25

Well Wololol I bet your hoping they are negotiating to buy the whole outfit rather than pay the license fees they have agreed to, as the cost to them would be minimal at the moment by comparison. Even at 10p a share it would be a snip, as not only would they make savings, they would also benefit from all the other potential big earners that could make them mega bucks over a period of time and transform this Swiss company into the big time.

Nice dreams and good luck but the real winners will be those that benefit from the development and research that has been completed, as their lives will improve.

[wololol] 12/10/2023 06:13

From Stalicla Website: they are fully invested in this; STP2STP2, or SFX-01, is a stabilized synthetic form of sulforaphane for which STALICLA has acquired the rights for neurodevelopment disorders worldwide from Evgen Pharma in Oct. 2022.STP2 a precision medicine treatment candidate identified by DEPI to benefit ASD-Phen2.ASD-Phen2 is the second DEPI-enriched subgroup of ASD patients, clinically validated in a clinical observational/biosampling study and showing a specific molecular signature as predicted by DEPI.STP2 will enter Phase 2 in 2023.

[hatfullofsky] 10/10/2023 19:13

I hope you are right On Target

[clocktower] 10/10/2023 15:10

Well it's Breast Cancer awareness month, so maybe there well be breaking news any moment from EVG.





"Research work is ongoing on the role of SFX-01 in relation to the development of resistance to certain CDK4/6 inhibitors."

"Breast cancer is the largest cause of cancer deaths in women worldwide. In around 75% of breast cancers, the hormone oestrogen plays a key part in tumour growth.

Evgen sponsored a Phase II trial [STEM – SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer] in patients with ER+, HER2-ve metastatic breast cancer (mBC). The study enrolled 46 patients with oestrogen-positive mBC who had all previously received treatment with either tamoxifen, an aromatase inhibitor (AI) or fulvestrant. Prior to entry to the STEM trial, patients previously responded to their current hormone therapy for at least six months but then presented with progressive disease, thereby demonstrating the start of resistance to the hormone therapy."

[on target] 10/10/2023 14:41

Stalicla are not some huge mega-corporation with a massive pipeline of projects who might decide to de-prioritise ASD in favour of something completely different.
They are completely focused on the precision treatment of ASD and other NDDs and Evgen is a key part of their strategy.

[kingalf] 10/10/2023 14:31

What beyond December 2024 that they recently moved it to. The bods have had an easy ride up until now. Huw destroyer of companies is certainly living up to his name, another notch on his desk. Any director linked to more than 2 companies that have gone under should really be struck off. It's clearly not for them.

[hatfullofsky] 10/10/2023 14:04

Big Pharma are reducing investment in early stage speculative projects so I expect EVG have been (incorrectly) caught in that exodus. Most of our near term news flow items are being pursued at education and research facilities. However I wouldn't be surprised to see Stailcla reset their timelines.

[hatfullofsky] 10/10/2023 14:01

There's not been the same level of selling as we saw in September. I wonder if the seller had a Q3 timeline.

[clocktower] 10/10/2023 12:59

Wololol it's been around a year since any new deal was done, and they have had jollies in the USA etc trying to drum up new partners, it seems without luck, and all this time they have made the excuse that they could not buy shares - pull the other one. We have to accept that it seems that was nothing more than spiel.

However, it is surprising that it never bounced off 2p even by 20%, as a dead cat bounce when you see the likes of Valirx (VAL) bounce from under 6p to around 11p and stay up pretty well,even though the company states they know no reason for the increase.

The fall has been a drip drip effect from around 5p going down in 2/3% drops with very few upcycles on the way.

Unless there is very positive news, as soon as there is a spike, be it from 1.5p or near to what we are I will sell the very few I have into it and hope to break even on those few, having taken a pretty hefty loss on the larger number I had before cutting my losses at circa 2.5p.

[wololol] 10/10/2023 12:23

One expects good news very soon ;)

[kingalf] 10/10/2023 12:04

What's really annoying is all the radio silence.
The optimist in me thinks they could be working on some deal in the background and hence all the silence, the reality is probably that they are way too busy with all their other jobs to worry about Evgen.